Early data suggest that IL-6 inhibitors may improve outcomes in COVID-19 patients by reducing respiratory complications and potentially aiding recovery in co-infected burn patients by minimizing immune system overactivation [77, 78]. The gene discussed is IL6; the disease is COVID-19.